ArticleImmunity, inflammation and disease2021
Silenced SOX2-OT alleviates ventricular arrhythmia associated with heart failure by inhibiting NLRP3 expression via regulating miR-2355-3p.
Article in Immunity, inflammation and disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 25 citations in OpenAlex.
- SOX2-OT serves as a diagnostic and prognostic biomarker for hypertensive left ventricular hypertrophy by targeting miR-30d-5p.Molecular and cellular biochemistry · 2026Article
- MND1 regulates PANoptosis and stemness of lung adenocarcinoma cells by stabilizing RCOR2 mRNA.Cell death & disease · 2026Article
- Clinical significance and mechanistic study of SOX2-OT and miR-27b-3p expression in children with viral myocarditis.BMC pediatrics · 2026Article
- The emerging role of long non-coding RNA SOX2-OT in cancers and non-malignant diseases.Journal of physiology and biochemistry · 2025Review
- Active ingredients of traditional Chinese medicine inhibit NOD-like receptor protein 3 inflammasome: a novel strategy for preventing and treating heart failure.Frontiers in immunology · 2025Review
- Emerging Role of Long Noncoding RNAs in Regulating Inflammasome-Mediated Neurodegeneration in Parkinson's Disease.Molecular neurobiology · 2024Review
- Downregulation of fibromodulin attenuates inflammatory signaling and atrial fibrosis in spontaneously hypertensive rats with atrial fibrillation via inhibiting TLR4/NLRP3 signaling pathway.Immunity, inflammation and disease · 2023Article
- Non-Coding RNAs and Gut Microbiota in the Pathogenesis of Cardiac Arrhythmias: The Latest Update.Genes · 2023Review
- The Effects of MicroRNAs in the Development of Heart Failure.Current cardiology reports · 2023Review
- Noncoding RNAs as Key Regulators for Cardiac Development and Cardiovascular Diseases.Journal of cardiovascular development and disease · 2023Review
- Chronic Coronary Syndrome in Frail Old Population.Life (Basel, Switzerland) · 2022Review
- Article
- Diagnostic and prognostic value of microRNA-2355-3p and contribution to the progression in lung adenocarcinoma.Bioengineered · 2021Article
- Silenced SOX2-OT alleviates ventricular arrhythmia associated with heart failure by inhibiting NLRP3 expression via regulating miR-2355-3p.Immunity, inflammation and disease · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundNucleotide-binding oligomerization domain-like receptor family pyrin domain containing 3 (NLRP3) inflammasomes are the most important factors in ventricular arrhythmia associated with heart failure (VA-HF). However, how the relationship between lncRNA and NLRP3 inflammasomes is regulated in VA-HF has not been investigated in detail. Thus, we aimed to determine the effects of SOX2-overlapping transcripts (SOX2-OT) by targeting NLRP3 in rats with VA-HF.
methodsWe established rats (SPF, male, weight: 240 ± 10 g) with VA-HF by aortic coarctation and constant-current stimulation, then injected them with small interfering SOX2-OT and anti-miR-2355-3p. Six weeks later, SOX2-OT and miR-2355-3p expression was measured using the quantitative reverse transcriptase-polymerase chain reaction and NLRP3, ASC, caspase-1, IL-1β, and TGF-β1 expression were measured by Western blot analysis; the ventricular chambers were histopathologically analyzed by staining with hematoxylin and eosin, Masson trichrome, and Picro Sirius Red and reactive oxygen species (ROS) levels were assessed by flow cytometry. The targeting relationship between miR-2355-3p and SOX2-OT or NLRP3 was verified using dual-luciferase reporter gene assays.
resultsThe expression of SOX2-OT and levels of NLRP3 inflammasomes gradually increased in normal rats, and in those with heart failure and with VA-HF. Silencing SOX2-OT expression inhibited NLRP3, ASC, caspase-1, IL-1β, and TGF-β1 expression and ROS production, reduced the degrees of cardiomyocyte necrosis and fibrosis and alleviated cardiac dysfunction in rats with VA-HF. MicroR-2355-3p can bind the SOX2-OT and the 3'-untranslated region of NLRP3. Inhibiting miR-2355-3p reversed the effect of SOX2-OT in rats with VA-HF.
conclusionsSilencing SOX2-OT alleviated cardiac dysfunction in rats by reducing the activation of NLRP3 inflammasomes via regulating miR-2355-3p.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.